Drug intelligence / Profile preview

LHNVD-603

Development stage: Preclinical
Lead developer: Longhorn Vaccines and Diagnostics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LHNVD-603 is a half-life-extended monoclonal antibody under development by Longhorn Vaccines and Diagnostics for the prevention and treatment of influenza. It is designed to target the highly conserved influenza matrix protein, a critical structural component of the virus. By binding to this conserved target, LHNVD-603 aims to provide broad-spectrum, long-lasting passive immunization that remains effective across evolving influenza strains. The candidate is currently in the IND-enabling stage of development.

Targets

M2e (Influenza A matrix protein 2 ectodomain)

Beyond the preview

Go deeper on LHNVD-603.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LHNVD-603.

Explore the full profile